BLISS GVS PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 104 INR | +0.09% |
|
+0.24% | -16.60% |
| 06-20 | Crisil Keeps BBB+ Rating on Bliss GVS Pharma's Bank Loans; Outlook Stable | MT |
| 05-02 | Bliss GVS Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| Sales 2022 | 7.47B 89.6M 123M | Sales 2023 | 7.52B 90.09M 123M | Capitalization | 7.42B 88.95M 122M |
|---|---|---|---|---|---|
| Net income 2022 | 150M 1.8M 2.46M | Net income 2023 | 709M 8.5M 11.63M | EV / Sales 2022 | 1.03 x |
| Net cash position 2022 | 256M 3.06M 4.19M | Net Debt 2023 | 335M 4.02M 5.5M | EV / Sales 2023 | 1.03 x |
| P/E ratio 2022 |
53.8
x | P/E ratio 2023 |
10.6
x | Employees | 763 |
| Yield 2022 |
0.65% | Yield 2023 |
0.7% | Free-Float | 34.77% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.09% | ||
| 1 week | +0.24% | ||
| Current month | +1.03% | ||
| 1 month | -2.52% | ||
| 3 months | -6.47% | ||
| 6 months | -17.26% | ||
| Current year | -16.60% |
1 week
101.52
106.89
1 month
92.15108.40
Current year
92.15142.40
1 year
75.45149.60
3 years
66.10149.60
5 years
66.10221.00
10 years
43.40221.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 41 | 21-01-20 | |
Deepak Sawant
DFI | Director of Finance/CFO | 44 | 22-12-29 |
| Compliance Officer | - | 15-11-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 81 | 11-07-31 | |
| Director/Board Member | 40 | 08-07-28 | |
| Director/Board Member | 39 | 06-07-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-24 | 104 | +0.09% | 310 439 |
| 24-06-21 | 103.9 | +0.82% | 547,617 |
| 24-06-20 | 103 | +0.86% | 306,914 |
| 24-06-19 | 102.2 | -1.50% | 361,745 |
| 24-06-18 | 103.7 | -2.02% | 645,648 |
Delayed Quote NSE India S.E., June 24, 2024 at 07:43 am
More quotes
Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Companyâs product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Companyâs other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
Sector
Pharmaceuticals
Calendar
2024-07-17
- Détachement de for final dividend
| 1st Jan change | Capi. | |
|---|---|---|
| +18.66% | 42.12B | |
| +23.31% | 21.72B | |
| +20.71% | 14.89B | |
| +56.75% | 13.06B | |
| -0.05% | 6.79B | |
| -12.68% | 6.3B | |
| +20.03% | 6.05B | |
| -8.87% | 5.73B | |
| +6.29% | 4.58B |
- Stock Market
- Equities
- BLISSGVS Stock
- BLISSGVS Stock
